Codexis Inc. [CDXS] stock prices are up 29.69% to $4.15 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CDXS shares have gain 43.60% over the last week, with a monthly amount glided 49.28%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche. In a post published today on Yahoo Finance, Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for next-generation sequencing (NGS) library preparation and the Company’s EvoT4™ DNA ligase. Under the terms of the deal, Codexis will receive upfront and technical milestone payments. This deal supersedes the prior exclusive license on the EvoT4™ DNA ligase.
From an analyst’s perspective:
Codexis Inc. [NASDAQ: CDXS] stock has seen the most recent analyst activity on November 07, 2023, when The Benchmark Company downgraded its rating to a Hold. Previously, TD Cowen downgraded its rating to Market Perform on August 07, 2023, and dropped its price target to $4. On May 09, 2023, downgrade downgraded it’s rating to Neutral. Piper Sandler started tracking with a Overweight rating for this stock on April 12, 2021, and assigned it a price target of $32. In a note dated March 01, 2021, Stifel initiated an Buy rating and provided a target price of $30 on this stock.
The stock price of Codexis Inc. [CDXS] has been fluctuating between $1.45 and $5.07 over the past year. Codexis Inc. [NASDAQ: CDXS] shares were valued at $4.15 at the most recent close of the market.
Analyzing the CDXS fundamentals
The Codexis Inc. [NASDAQ:CDXS] reported sales of 73.96M for trailing twelve months, representing a drop of -73.09%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.45 points at the first support level, and at 2.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.64, and for the 2nd resistance point, it is at 5.13.
Codexis Inc. [CDXS] reported earnings per share of -$0.5 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.32/share, meaning a difference of -$0.18 and a surprise factor of -56.20%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.17 per share as compared to estimates of -$0.21 per share, a difference of $0.04 representing a surprise of 19.00%.
Ratios To Look Out For
It’s worth pointing out that Codexis Inc. [NASDAQ:CDXS]’s Current Ratio is 2.68. As well, the Quick Ratio is 2.62, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 3.92, the price to book ratio is 3.17.
Transactions by insiders
Recent insider trading involved Dorgan Byron L, Director, that happened on Nov 15 when 20000.0 shares were sold. Chief Operating Officer, Norrett Kevin completed a deal on Sep 11 to buy 9000.0 shares. Meanwhile, DILLY STEPHEN GEORGE bought 58479.0 shares on Sep 08.
